Adam Cuker - "Monitoring unfractionated heparin: best practices and controversies"
Dr. Cuker will review evidence, controversies, and best practices in the measurement and monitoring of unfractionated heparin, low molecular weight heparin, and fondaparinux.
Gualtiero Palareti - "Monitoring of direct oral anticoagulants"
Dr. Palareti will review in which circumstances and for which purposes measuring the concentration of the direct oral anticoagulants (DOACs) is indicated and which are the laboratory assays that should be used for this scope and those that are not recommended.
Clinicaians and laboratory professional involved in the management of patients on anticoagulant therapy
At the conclusion of this activity, I will be able to:
- Understand the evidence for and against laboratory monitoring of unfractionated heparin.
- Identify indications for measurement of low molecular weight heparin and fondaparinux.
- Describe current best practices for monitoring and measurement of unfractionated heparin, low molecular weight heparin, and fondaparinux.
- Understand the difference between monitoring and measuring anticoagulant agents
- Learn in which circumstances measuring the concentration of DOACs can help clinical management decisions
- Understand which are the assays that are recommended to measure the effect of dabigatran, rivaroxaban, apixaban and edoxaban
- Understand which are the limitations of routine coagulation assays for this scope and why their use is not recommended to measure the anticoagulant effect of DOACs
- Understand which are the specific effects of DOACs on tests of hemostasis
Dr. Adam Cuker will review evidence, controversies, and best practices in the measurement and monitoring of unfractionated heparin, low molecular weight heparin, and fondaparinux.
Gualtiero Palareti "Monitoring of direct oral anticoagulants"
Dr. Gualtiero Palareti will review in which circumstances and for which purposes measuring the concentration of the direct oral anticoagulants (DOACs) is indicated and which are the laboratory assays that should be used for this scope and those that are not recommended.
Moderator:
Geoff Barnes
Name | Company | Role |
Geoffrey Barnes, MD | Portola | Consulting |
Blue Cross Blue Shield of Michigan | Research | |
BMS/Pfizer | Research | |
Chris Ward, PhD | Bayer | Speaker |
Boehringer-Ingelheim | Speaker, Advisory Board | |
BMS/Pfizer | Speaker, Advisory Board | |
Adam Cuker, MD | Amgen | Consultant |
Genzyme | Consultant | |
Bracco Diagnostic Imaging | Consultant | |
Gualtiero Palareti, MD | Alfa-Wassermann | Advisory Board |
Daiichi-Sankyo | Advisory Board | |
Instrumentation Laboratory/Werfen | Speaker | |
Siemens | Speaker | |
Stago | Speaker |
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved.
Contact
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.